Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for February 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during February 2014.

For an indepth analysis of these deals, read 'Pharma deals during February 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Forest Laboratories / ActavisCompany acquisition
Speciality pharma with strong CNS portfolio
25,000
Ablynx / Merck & Co
Collaboration
Nanobody candidates to target “immune checkpoint modulators”
2,331
Cadence Pharmaceuticals / Mallinckrondt
Company acquisition
Ofirmev (acetaminophen) for pain
1,300
Adcock Ingram / CFR Pharmaceuticals
Acquisition termination
South African generics company
1,225
Medpace / Cinven
Acquisition – majority shareholding
US mid-sized CRO with global presence
915
Cellectis / Servier
Licence
Product candidates for solid tumours, UCART19 (allogenic CAR-T) for leukaemia and lymphomas (6 candidates in total)
850
PreCision Dermatology / Valeant Pharmaceuticals
Company acquisition
Medical dermatological products
500
Crescendo Bioscience / Myriad Genetics
Company acquisition
Medical diagnostic tool for autoimmune diseases
270
Discuva / Roche
Collaboration
Antibiotics to target multi-drug resistant Gram negative bacteria
201
Ardelyx (formerly Nteryx) / Sanofi
Licence1
NaP2b inhibitor programme for ESRD2 and CKD3
198
Zosano (formerly Macroflux) / Novo Nordisk
Development
Semaglutide once weekly, ZP Patch Technology
115
Andromeda / Teva Pharmaceutical Industries
Licence termination
DiaPep277 for type 1 diabetes patients
72
Manchester Pharmaceuticals / Retrophin
Company acquisition
Rare disease company with marketed products in US (Chenodal to treat CTX4)
63
Apricus Biosciences (formerly NexMed) / Recordati
Licence
Vitaros topical treatment for erectile dysfunction
51
Abide Therapeutics / Celgene
Option  and equity investment
Inflammatory and immunology target for catalytic of serine hydrolases for CNS signalling
50
4-Antibody AG / Aegenus
Company acquisition
Retrocyte Display technology platform
40
UDG Healthcare / Professional Compounding Centers of America
Company acquisitions
UDG subsidiaries : The Specials Laboratory Holdings, Craig & Hayward, Arjun Products
39
Novo Nordisk / Innate Pharma
Licence with equity partial payment
Phase II ready Anti-NKG2A antibody “immune checkpoint inhibitor”
30
Servier / MacroGenics
Option exercise
MGD006, a DART-based product candidate for haematological malignancies
15
Forest Labs / Hospira (via Mayne Pharma)
Acquisition products
Esgic, ESGIC PLUS, Lorcet, LORCET PLUS – portfolio of pain products
12


1. Co-promotion rights in US
2. Endstage renal disease
3. Chronic kidney disease
4. Cerebrotendinous xanthomatosis
 

The Deal Watch table is compiled by Medius Associates

14th March 2014

The Deal Watch table is compiled by Medius Associates

14th March 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Infographics